Bioavailability of BI 1356 and Glyburide in Healthy Male and Female Volunteers
- Registration Number
- NCT02183428
- Lead Sponsor
- Boehringer Ingelheim
- Brief Summary
The objective of this study was to investigate the effect of multiple doses BI 1356 given once daily in the estimated highest therapeutic dose of 5 mg until steady state on the pharmacokinetics, safety, and tolerability of a single oral conventional therapeutic dose of 1.75 mg glyburide. In addition, the effect of glyburide as a single oral dose of 1.75 mg being a conventional therapeutic dose on the multiple dose pharmacokinetics of BI 1356 was investigated. Pharmacokinetic profiles of glyburide were determined when given alone or in combination with BI 1356. Pharmacokinetic profiles of BI 1356 and its inactive metabolite CD 1750 were determined at steady state of BI 1356 when given alone or in combination with glyburide.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 20
Inclusion Criteria
- Healthy females and males according to the following criteria: Based upon a complete medical history, including the physical examination, vital signs (Blood Pressure (BP), Pulse Rate (PR)), 12-lead (ECG) Electrocardiogram, clinical laboratory tests
- Age ≥18 and Age ≤55 years
- BMI ≥18.5 and BMI ≤29.9 kg/m2 (Body Mass Index)
- Signed and dated written informed consent prior to admission to the study in accordance with Good Clinical Practice and the local legislation
Exclusion Criteria
- Any finding of the medical examination (including BP, PR and ECG) deviating from normal and of clinical relevance
- Any evidence of a clinically relevant concomitant disease
- Gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic, immunological or hormonal disorders
- Surgery of the gastrointestinal tract (except appendectomy)
- Diseases of the central nervous system (such as epilepsy) or psychiatric disorders or neurological disorders
- History of relevant orthostatic hypotension, fainting spells or blackouts
- Chronic or relevant acute infections
- History of relevant allergy or hypersensitivity (including allergy to drug or its excipients)
- Intake of drugs with a long half-life (> 24 hours) within at least one month or less than 10 half-lives of the respective drug prior to administration or during the trial
- Use of drugs which might reasonably influence the results of the trial or that prolong the QT/QTc interval based on the knowledge at the time of protocol preparation within 10 days prior to administration or during the trial, including herbal products
- Participation in another trial with an investigational drug within two months prior to administration or during the trial
- Smoker (> 10 cigarettes or > 3 cigars or > 3 pipes/day)
- Inability to refrain from smoking on trial days
- Alcohol abuse (more than 60 g/day)
- Drug abuse
- Blood donation (more than 100 mL within four weeks prior to administration or during the trial)
- Excessive physical activities (within one week prior to administration or during the trial)
- Any laboratory value outside the reference range that is of clinical relevance
- Inability to comply with dietary regimen of trial site
- A marked baseline prolongation of QT/QTc interval (e.g., repeated demonstration of a QTc interval >450 ms)
- A history of additional risk factors for torsade de pointes (e.g., heart failure, hypokalaemia, family history of Long QT Syndrome)
- Galactose intolerance
- Lactase deficiency
- Glucose-galactose-malabsorption
For all female subjects:
- Pregnancy or planning to become pregnant within 2 months of study completion
- Positive pregnancy test
- No adequate contraception e.g. , sterilisation, IUD (intrauterine device), have not been using a barrier method of contraception for at least 3 months prior to participation in the study
- Not willing or unable to use a reliable method of barrier contraception (such as diaphragm with spermicidal cream/jelly or condoms with spermicidal foam), during and up to 2 months after completion/termination of the trial
- Partner is unwilling to use condoms
- Lactation period
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- CROSSOVER
- Arm && Interventions
Group Intervention Description BI 1356 BI 1356 Treatment sequence AB_C or C_AB * Treatment A: 5 days of treatment with BI 1356 once per day until steady state followed by * Treatment B: 1 day of combined treatment of BI1356 and glyburide * Treatment C: 1 day of treatment with glyburide alone BI 1356 Glyburide Treatment sequence AB_C or C_AB * Treatment A: 5 days of treatment with BI 1356 once per day until steady state followed by * Treatment B: 1 day of combined treatment of BI1356 and glyburide * Treatment C: 1 day of treatment with glyburide alone BI 1356 BI 1356 + Glyburide Treatment sequence AB_C or C_AB * Treatment A: 5 days of treatment with BI 1356 once per day until steady state followed by * Treatment B: 1 day of combined treatment of BI1356 and glyburide * Treatment C: 1 day of treatment with glyburide alone Glyburide BI 1356 Treatment sequence AB_C or C_AB * Treatment A: 5 days of treatment with BI 1356 once per day until steady state followed by * Treatment B: 1 day of combined treatment of BI1356 and glyburide * Treatment C: 1 day of treatment with glyburide alone Glyburide Glyburide Treatment sequence AB_C or C_AB * Treatment A: 5 days of treatment with BI 1356 once per day until steady state followed by * Treatment B: 1 day of combined treatment of BI1356 and glyburide * Treatment C: 1 day of treatment with glyburide alone Glyburide BI 1356 + Glyburide Treatment sequence AB_C or C_AB * Treatment A: 5 days of treatment with BI 1356 once per day until steady state followed by * Treatment B: 1 day of combined treatment of BI1356 and glyburide * Treatment C: 1 day of treatment with glyburide alone
- Primary Outcome Measures
Name Time Method Cmax (maximum measured concentration of glyburide in plasma) for several time points up to 48 hours after drug administration Cmax,ss (maximum measured concentration of the analyte in plasma at steady state over a uniform dosing interval τ) of BI 1356 up to 48 h after drug administration AUC0-infinity (area under the concentration-time curve of glyburide in plasma) for several time points up to 48 hours after drug administration AUCτ,ss (area under the concentration-time curve of the analyte in plasma at steady state over a uniform dosing interval τ) of BI 1356 up to 48 h after drug administration
- Secondary Outcome Measures
Name Time Method tmax (time from dosing to the maximum concentration of the analyte in plasma) for several time points up to 48 hours after drug administration λz (terminal rate constant in plasma) up to 48 hours after drug administration Assessment of tolerability by investigator on a 4-point scale Day 1 of treatment B, day 3 of treatment B and C AUC (area under the concentration-time curve of the analyte in plasma) for several time points up to 48 h after drug administration CL/F (apparent clearance of the analyte in the plasma after extravascular administration) for several time points up to 48 hours after drug administration t1/2 (terminal half-life of the analyte in plasma) up to 48 hours after drug administration MRTpo (mean residence time of the analyte in the body after po administration) for several time points up to 48 hours after drug administration Vz/F (apparent volume of distribution during the terminal phase λz following an extravascular dose) for several time points up to 48 hours after drug administration Number of patients with adverse events up to 11 weeks Cmax,ss (maximum measured concentration of the analyte in plasma at steady state over a uniform dosing interval τ) of CD 1750 up to 48 h after drug administration